CredoScientia - Bibliothèque

Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.

Triple therapy (TT), consisting of transarterial chemoembolization, immune checkpoint inhibitors, and tyrosine kinase inhibitors, is recommended as a conversion therapy for patients with unresectable …

Thérapies de Conversion

Zhou, Y., Yao, M., Wen, T., & Li, C. (2025). Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.. Biosci Trends, 19(4), 468-478. https://doi.org/10.5582/bst.2025.01170

17/09/2025 Lire →

Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.

OBJECTIVES: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to bene…

Thérapies de Conversion

Huang, X., Chen, X., Chen, J., Hu, C., Chen, H., Chen, H., Fang, J., Ye, Z., Du, Y., Yu, P., & Huang, L. (2025). Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.. Cancer Immunol Immunother, 74(10), 302. https://doi.org/10.1007/s00262-025-04161-6

11/09/2025 Lire →

An Interview Tool for Identifying Sexual Orientation or Gender Identity and Expression Change Efforts in Queer Youth.

Sexual orientation, gender identity, and gender expression change efforts (SOGIECE), including, but not limited to, conversion therapy, describe explicit attempts to suppress or change someone's sexua…

Thérapies de Conversion

Yu, L., Dalke, K., & Eckstrand, K. (2025). An Interview Tool for Identifying Sexual Orientation or Gender Identity and Expression Change Efforts in Queer Youth.. J Am Acad Child Adolesc Psychiatry. https://doi.org/10.1016/j.jaac.2025.08.558

03/09/2025 Lire →

Unqueering the Double Helix: Conversion Therapists, the "Gay Gene," and Culture Wars in the United States.

In 1993, geneticist Dean Hamer and his colleagues published a groundbreaking study suggesting that a region on the X chromosome-Xq28-might be linked to male homosexuality. Widely covered in the press …

Thérapies de Conversion

Babits, C. (2025). Unqueering the Double Helix: Conversion Therapists, the "Gay Gene," and Culture Wars in the United States.. Yale J Biol Med, 98(3), 259-271. https://doi.org/10.59249/YADT3005

01/09/2025 Lire →

Considerations on the rationale and real-world applicability of conversion therapy in gastric cancer with peritoneal metastasis correspondence.

Thérapies de Conversion

Gong, Y., Chen, S., & Sun, F. (2025). Considerations on the rationale and real-world applicability of conversion therapy in gastric cancer with peritoneal metastasis correspondence.. Int J Surg, 111(9), 6573-6574. https://doi.org/10.1097/JS9.0000000000002754

01/09/2025 Lire →

Tremelimumab for the treatment of hepatocellular carcinoma.

INTRODUCTION: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality globally. For years, systemic treatment options were limited to tyrosine kinase inhibitors with modest outcomes…

Thérapies de Conversion

Sogbe, M., Sangro, P., de, l. a. . T. o. r. r. e. -. A. l. �. �. e. z. . M., & Sangro, B. (2025). Tremelimumab for the treatment of hepatocellular carcinoma.. Expert Opin Biol Ther, 25(9), 925-934. https://doi.org/10.1080/14712598.2025.2550711

01/09/2025 Lire →

Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.

Thérapies de Conversion

Yang, D. L., Li, Y. F., Li, Y. J., Qiu, G. G., Liu, Z. D., Zhang, Y. G., Chen, H., & Zhong, J. H. (2025). Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.. Hepatology, 82(3), E105-E106. https://doi.org/10.1097/HEP.0000000000001395

01/09/2025 Lire →

Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.

Thérapies de Conversion

Wang, D., Yi, S., & Liu, X. (2025). Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.. Hepatology, 82(3), E103-E104. https://doi.org/10.1097/HEP.0000000000001390

01/09/2025 Lire →

Comparison of machine learning and Cox regression models for prognostic analysis in hepatocellular carcinoma patients with distant metastasis.

BACKGROUND: With the development of conversion therapy, there has been a significant improvement in advanced stage hepatocellular carcinoma (HCC) patients' survival outcomes. Accurate prognostic asses…

Thérapies de Conversion

Li, H., Wang, J., Ming, X., Zhou, M., & Zhou, L. (2025). Comparison of machine learning and Cox regression models for prognostic analysis in hepatocellular carcinoma patients with distant metastasis.. Surg Open Sci, 27, 36-44. https://doi.org/10.1016/j.sopen.2025.06.007

01/09/2025 Lire →

Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.

BACKGROUND: Conversion therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) offers the potential for curative resection in unresectable hepatocellular carcinoma (HCC)…

Thérapies de Conversion

Lin, K. Y., Liu, H. Z., Liu, J. W., Zhu, X. D., Pan, Y. X., Shen, S. L., Zhang, W., Jin, R. A., Han, C. Y., Chen, J., Zhang, X. Y., Liang, B. Y., Zhang, Y. D., Ma, J., Wang, N. Y., Li, D. X., Xiong, R., Li, Z. C., Li, J. D., … China, L. i. v. e. r. . C. a. n. c. e. r. . S. t. u. d. y. . G. r. o. u. p. . Y. o. u. n. g. . I. n. v. e. s. t. i. g. a. t. o. r. s. . (. C. L. E. A. P. ). (2025). Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.. Eur J Surg Oncol, 51(9), 110220. https://doi.org/10.1016/j.ejso.2025.110220

01/09/2025 Lire →

First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report.

Immunotherapy shows limited efficacy in microsatellite-stable (MSS) colorectal cancer. This case report describes a 40-year-old male with left-sided kirsten rat sarcoma viral oncogene homolog (KRAS)/v…

Thérapies de Conversion

Zhang, Y., Wang, D., Zhang, K., Li, S., & Yu, C. (2025). First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report.. Anticancer Drugs, 36(8), 686-690. https://doi.org/10.1097/CAD.0000000000001736

01/09/2025 Lire →

The combination of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), interventional hepatoma therapy, targeted therapy, and immunotherapy: a case series of a novel AITI conversion therapy model.

BACKGROUND: Conversion therapy has been a hot field of hepatocellular carcinoma (HCC). The combination of interventional hepatoma therapy, targeted therapy and immunotherapy is an emerging conversion …

Thérapies de Conversion

Chen, Z., Chen, X., Hu, H., Chen, K., Xiao, H., Du, C., & Lan, X. (2025). The combination of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), interventional hepatoma therapy, targeted therapy, and immunotherapy: a case series of a novel AITI conversion therapy model.. J Gastrointest Oncol, 16(4), 1736-1748. https://doi.org/10.21037/jgo-2025-204

30/08/2025 Lire →